Evaluating Renal Masses Using Ultrasound Intravenous Microbubble Contrast
Completed · Phase 1
Conditions studied: Renal Cancer, Kidney Cancer
In brief
The purpose of this study is to evaluate the blood flow in kidney masses by using ultrasound microbubble contrast material, and to see if results from ultrasound contrast studies can predict if a kidney mass is benign or malignant. Patterns of blood flow in the kidney mass will be examined to see if: 1. benign kidney masses can be distinguished from kidney cancers and 2. if slow growing, lower risk cancers have different blood flow compared to clear cell cancer which is the most common type of kidney cancer.
Key facts
- Study ID
- NCT00671411
- Run by
- Memorial Sloan Kettering Cancer Center
- People needed
- 42
- Starts
- 2008-03-01
- Expected to finish
- 2011-11-01
- Last updated by the study team
- 2015-12-28
Who can join
Age: 21 and older, up to 99. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Any adult patient who is planned or scheduled for surgical excision or biopsy of a solid or complex cystic renal mass would be eligible for the study
- Histology of the renal mass must be unknown at the time of enrollment
- Patients who have renal masses that are evident on conventional US imaging
- Patients will have a correlative abdominal CT and/or MRI
You may not qualify if…
- Patients with any history of cardiac shunts.
- Patients with history of pulmonary hypertension or unstable cardiopulmonary conditions, including patients on mechanical ventilation.
- Patients without peripheral IV access
- Pregnant patients and children
- Patients with any known contrast allergies, allergy to perflutren, or any components of Definity or microbubble contrast
- Patients who have renal masses that are not evident on conventional US imaging
Where it is running
- Memorial Sloan-Kettering Cancer Center — New York, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.